UNITY Biotechnology

UBX51

Penny Stock

$1.45arrow_drop_up0.69%$0.01

Penny Stock

UBX51

$1.45

arrow_drop_up0.69%$0.01

Penny Stock

Performance History

Key Stats
Open	$1.47
Prev. Close	$1.44
EPS	-1.92
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$24.26M
PE Ratio	-

	LOW	HIGH
Day Range	1.44	1.47
52 Week Range	1.22	2.47

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.92

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About UNITY Biotechnology (UBX)

UNITY Biotechnology Inc (UBX) is a biotechnology company that focuses on the development of therapeutics to extend human healthspan, or the period of life free from age-related diseases. The company's primary therapeutic approach is to selectively eliminate senescent cells, which are cells that have entered a state of irreversible growth arrest and accumulate with age. By clearing these senescent cells from the body, UNITY aims to address the underlying cause of many age-related conditions, such as osteoarthritis, age-related macular degeneration, and kidney disease.

UBX stock has seen significant fluctuations in its price history. It started trading on the NASDAQ exchange in 2018, and since then, it has experienced both ups and downs. In recent years, the stock has shown a relatively volatile pattern, with frequent changes in its value. Investors interested in UBX should closely monitor the stock price fluctuations and assess the market conditions before making any investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Anirvan Ghosh Ph.D.
Headquarters: South San Francisco
Employees: 22
Exchange: NASDAQ

Keep an eye on UNITY Biotechnology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is UNITY Biotechnology (UBX) stock price performance year to date (YTD)?

As of the latest data, UNITY Biotechnology (UBX) has a year-to-date price change of -24.48%. Over the past month, the stock has experienced a price change of -13.17%. Over the last three months, the change has been 5.07%. Over the past six months, the figure is -11.04%. Looking at a longer horizon, the five-year price change stands at -97.67%.

help

What is the market capitalization of UNITY Biotechnology (UBX)?

UNITY Biotechnology (UBX) has a market capitalization of $24.26M. The average daily trading volume is 26.87K, indicating the stock's liquidity and investor engagement.

help

What is UNITY Biotechnology 's (UBX) price per share?

The current price per share for UNITY Biotechnology (UBX) is $1.45. The stock has seen a price change of $0.01 recently, indicating a 0.69% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for UNITY Biotechnology (UBX)?

For UNITY Biotechnology (UBX), the 52-week high is $2.47, which is 70.34% from the current price. The 52-week low is $1.22, the current price is 18.85% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is UNITY Biotechnology (UBX) a growth stock?

UNITY Biotechnology (UBX) has shown an average price growth of 0.41% over the past three years. It has received a score of 1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying UNITY Biotechnology as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

Is UNITY Biotechnology (UBX) a profitable company?

UNITY Biotechnology (UBX) has a net income of -$39.86M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$40.16M. Furthermore, the EBITDA is -$27.55M.